150915-41-6 Usage
Description
Perospirone hydrochloride was launched in Japan as a new treatment of schizophrenia
and other psychoses. This structurally-related analog of ziprasidone can be classically
prepared by alkylation of 1-(3-benzisothiazolyl)-piperazine with the appropriate N-
(chlorobutyl)-succinimide. As a result of an in vitro determination of its binding profile,
perospirone demonstrated a high affinity for 5-HT2, 5-HT1A and D2 receptors as well as a
significant but lower affinity for DI and al receptors. Interestingly, these differential effects
on neurotransmitters with a high in vivo occupancy of 5-HT2A receptors with lower D2
occupancy seems to provide this new agent with a significantly lower propensity for the
development of extrapyramidal symptoms (EPS) and tardive schizophrenia, the main sideeffects
associated with classical antipsychotic therapy. Furthermore, perospirone exhibited
anxiolytic-like effects in animal models. A long-term clinical trial (> 6 months) in a group of
patients suffering from schizophrenia demonstrated the efficacy of perospirone over
placebo for the treatment of the positive, negative and general symptoms of schizophrenia
at doses of 12 mg to 96 mg t.i.d.
Originator
Sumitomo Pharm. (Japan)
Brand name
Lullan
Check Digit Verification of cas no
The CAS Registry Mumber 150915-41-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,0,9,1 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 150915-41:
(8*1)+(7*5)+(6*0)+(5*9)+(4*1)+(3*5)+(2*4)+(1*1)=116
116 % 10 = 6
So 150915-41-6 is a valid CAS Registry Number.
InChI:InChI=1/C24H32N4O2S/c29-23-20-9-3-4-10-21(20)24(30)28(23)12-6-5-11-26-13-15-27(16-14-26)22-19-8-2-1-7-18(19)17-31-25-22/h1-2,7-8,20-21H,3-6,9-17H2/t20-,21+
150915-41-6Relevant articles and documents
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
-
, (2008/06/13)
The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.
